A Rare Laryngeal Tumor: Poorly Differentiated Primary Small Cell Neuroendocrine Carcinoma
B-ENT, 2023 Laryngeal small-cell neuroendocrine carcinoma is a rare and aggressive type of tumor. Due to the poor degree of differentiation, laryngeal small cell neuroendocrine carcinoma has particularly aggressive biological behavior with a tendency to early and ...
Arie Frank Arensman +4 more
doaj +2 more sources
Primary Small Cell Carcinoma of The Esophagus – An Eight Year Retrospective Study [PDF]
Journal of Clinical and Diagnostic Research, 2015 Introduction: Primary small cell carcinoma of the esophagus is a rare and aggressive tumor. Patients present with metastatic disease and have a poor clinical outcome.
Bhavna Nayal +6 more
doaj +1 more source
Histopathological Assessment for Esophageal Squamous Cell Carcinoma
, 2020 Histological assessment of esophageal squamous malignancies is crucial for management of patients with the cancer as well as working in research on the cancer.
Lam, AK, Alfred K. Lam
core +1 more source
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells [PDF]
, 2009 Background Treatment options for metastatic renal cell carcinoma (RCC) are limited due to resistance to chemo- and radiotherapy. The development of small-molecule multikinase inhibitors have now opened novel treatment options.
Natsheh, Iyad Y. M. +15 more
core +2 more sources
Peripheral lysosomes recruit PLEKHG3 to focal adhesions and restrain protrusion dynamics
FEBS Letters, EarlyView.Proximity‐dependent labeling at the LAMTOR complex revealed the Rho GEF PLEKHG3 as a lysosome‐proximal protein directing the study toward the influence of lysosome positioning on actin dynamics and cell motility. We show that PLEKHG3 colocalizes with lysosomes at focal adhesion sites and observe that forced peripheral dispersion of lysosomes hinders ...
Rainer Ettelt +8 more
wiley +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Cetuximab and biomarkers in non-small-cell lung carcinoma
Biologics: Targets & Therapy, 2012 Nitin Patil, Mohammed Abba, Heike AllgayerDepartment of Experimental Surgery, Medical Faculty Mannheim, University of Heidelberg and Molecular Oncology of Solid Tumors Unit, German Cancer Research Center (DKFZ), Heidelberg, GermanyAbstract: Cancer ...
Patil N, Abba M, Allgayer H
doaj
Extrapulmonary Small Cell Carcinoma of the Stomach: A Lethal Entity
Case Reports in Gastroenterology, 2010 Extrapulmonary small cell carcinoma of the stomach is a rare and aggressive malignancy with a poor prognosis that was first described in 1976 by Matsusaka et al.
Duane Moise +8 more
doaj +1 more source
Liver organoids: modelling complexity in homeostasis and disease
FEBS Letters, EarlyView.Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley +1 more source
Epigenetic reprogramming of lineage switching in cancer
FEBS Letters, EarlyView.Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source